78190-11-1

Usage

Chemical Properties

White solid

InChI:InChI=1/C14H17NO4/c16-13(17)12-7-4-8-15(9-12)14(18)19-10-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2,(H,16,17)/p-1/t12-/m0/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 498-95-3 nipecotic acid 
• 118156-93-7 3-formylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 174543-74-9 N-benzyloxycarbonyl nipecotic acid methyl ester 
• 216502-94-2 1-[(benzyloxy)carbonyl]piperidine-3-carbonyl chloride 
• 216502-71-5 3-{5-[(S)-2-tert-Butoxycarbonyl-2-(2,2,2-trifluoro-acetylamino)-ethyl]-2-methoxy-phenylcarbamoyl}-piperidine-1-carboxylic acid benzyl ester 
• 174543-80-7 3-Amino-3-methyl-piperidine-1-carboxylic acid benzyl ester 
• 174543-79-4 3-Carbamoyl-3-methyl-piperidine-1-carboxylic acid benzyl ester 
• 174543-78-3 1-((benzyloxy)carbonyl)-3-methylpiperidine-3-carboxylic acid 
• 174543-81-8 3-Acetylamino-3-methyl-piperidine-1-carboxylic acid benzyl ester 
• 174543-82-9 3-Methyl-piperidine-1,3-dicarboxylic acid 1-benzyl ester 3-methyl ester 
• 301180-04-1 tert-butyl N-benzyloxycarbonyl nipecotate 
• 310454-53-6 3-ethyl 1-(phenylmethyl) 1,3-piperidinedicarboxylate 
• 874361-32-7 3-(2-oxo-2-phenyl-ethylcarbamoyl)-piperidine-1-carboxylic acid benzyl ester 
• 405239-72-7 benzyl 3-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate 
• 256446-54-5 3-(2-phenyl-1H-indole-3-carbonyl)piperidine-1-carboxylic acid benzyl ester 
• 953821-03-9 benzyl 3-{[ethyl(isopropyl)amino]carbonyl}piperidine-1-carboxylate 

Relevant academic research and scientific papers

NEW LIPOGENESIS INHIBITOR COMPOUNDS

The present invention relates to Formula (I), wherein—if X=NH, each of R1, R2, R3, R4 represents a hydrogen atom; if X=N, the core is aromatic, and R2, R3 and R4 represent hydrogen atoms, and R1=H, halogen, aryl, heteroaryl, alkenyl or acetylenyl; or R1, R2, R3, R4 are defined such that R1 or R2 or R3 or R4 represents a methyl group, and the three other radicals represent a hydrogen atom.

Carbazole inhibitors of histamine receptors for the treatment of disease

The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES

This invention relates to a pharmaceutical comprising, as an active ingredient, a ureide derivative represented by formula: or a pharmaceutically acceptable salt thereof. The ureide derivative or a pharmaceutically acceptable salt thereof according to the present invention is useful for relieving pain and treating or preventing neuropathic pain.

Novel piperidyl derivatives of quinazoline and isoquinoline

The invention pertains to new piperidyl-substituted quinazoline and isoquinoline derivatives that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders.

CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives

Replacement of the 5-oxopyrrolidin-3-yl fragment in the previously reported lead structure with a 1-acetylpiperidin-4-yl group led to the discovery of a novel series of potent CCR5 antagonists. Introduction of small hydrophobic substituents on the central phenyl ring increased the binding affinity, providing low to sub-nanomolar CCR5 antagonists. The selected compound 11f showed excellent antiviral activity against CCR5-using HIV-1 replication in human peripheral blood mononuclear cells (EC50 = 0.59 nM) and an acceptable pharmacokinetic profile in dogs.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS

The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Pyridine derivatives

Pyridine compounds of general formula: wherein —R1represents in which R11is hydrogen, C1-6alkyl, halogen, hydroxy, C1-12alkoxy, nitro, amino, C1-6alkylsulfonylamino, C1-6alkoxycarbonyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkanoylamino, phenyl C1-6alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2represents hydrogen or halogen; R3represents hydrogen, —CR31R32R33, or —NR34R35; R4is hydrogen, carbamoyl, CN, carboxyl, etc.; R5is amino, C1-6alkylamino, di C1-6alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.